Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.
Bibliographical noteFunding Information:
Editorial support was funded by Eisai Inc. and provided by Imprint Publication Science, New York, NY, USA.
© 2014 The Authors.
Copyright 2015 Elsevier B.V., All rights reserved.
- Adverse effects
- Antiepileptic drugs